This is a few days old, but it will complete the record, here -- just couldn't get to it before (as a new graphic was needed). From BusinessWeek, of September 28, 2011 then:
. . . .Johnson & Johnson bought Merck & Co.’s half of the companies’ joint venture for over-the-counter medicines for heartburn and digestive diseases for $175 million, ending a 22-year partnership in the U.S. and Canada.
The deal. . . includes a manufacturing plant in Lancaster, Pennsylvania, that is part of a consent decree with U.S. regulators because of production violations. J&J, the world’s second-biggest seller of health products after Pfizer Inc., has recalled dozens of drugs and devices in the past two years, including nonprescription medicines such as Tylenol. . . .
So it goes -- this still leaves the recently-restructured prescription relationship on Simponi® (golimumab)/Remicade® in place between the companies, however -- post the arbitration settlement.
Now, Whitehouse Station says New Merck will be freed up to focus upon its legacy Schering-Plough Consumer Health offerings. We shall see.